Testing for prostate-specific antigen (PSA) has profoundly affected the diagnosis and
treatment of prostate cancer. PSA testing has enabled physicians to detect prostate tumours …

Answer questions and earn CME/CNE Prostate cancer survivors approach 2.8 million in
number and represent 1 in 5 of all cancer survivors in the United States. While guidelines …

Background Stereotactic body radiation therapy (SBRT) delivers fewer high-dose fractions of
radiation which may be radiobiologically favorable to conventional low-dose fractions …

Context In the United States, 192 000 men were diagnosed as having prostate cancer in
2009, the majority with low-risk, clinically localized disease. Treatment of these cancers is …

PURPOSE: The radiobiology of prostate cancer favors a hypofractionated dose regimen. We
report results of a prospective Phase II clinical trial of stereotactic body radiotherapy (SBRT) …

Prostate brachytherapy is a commonly used modality for the treatment of prostate cancer.
After prostate brachytherapy, the prostate-specific antigen (PSA) level may fluctuate and …

Background and purpose To identify a PSA threshold value at an intermediate follow-up
time after low dose rate (LDR) prostate brachytherapy associated with cure, defined as long …

PURPOSE: To report outcomes for 1,111 men treated with iodine-125 brachytherapy (BT) at
a single institution. METHODS AND MATERIALS: A total of 1,111 men (median age, 63) …

Background Carbon-ion radiotherapy (CIRT) for prostate cancer was initiated at Kanagawa
Cancer Center in 2015. The present study analyzed the preliminary clinical outcomes of …

Background: Interstitial brachytherapy for localised prostate cancer may be followed by
transient increases in prostate-specific antigen (PSA) that resolve without therapy. Such PSA …